Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 5 days ago

BridgeBio Oncology Therapeutics, Inc.: Flynn James E amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 13 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Flynn James E filed an amended Schedule 13G with the SEC (accession 0001193805-26-001463) updating his beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc. The amendment revises his previously reported position in the company's shares, though the filing did not disclose a change in share count or percentage in the headline. The disclosure matters because 13G amendments signal shifts in passive or institutional holdings that can influence investor sentiment around the clinical-stage oncology company. Investors will watch for further ownership updates and any corresponding changes in BridgeBio Oncology's share performance.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Flynn James E, BridgeBio Oncology Therapeutics, Inc.